Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer

被引:49
作者
Ling, Diane C. [1 ]
Vargo, John A. [1 ]
Ferris, Robert L. [1 ,2 ]
Ohr, James [3 ]
Clump, David A. [1 ]
Yau, Wai-Ying Wendy [1 ]
Duvvuri, Umamaheswar [2 ]
Kim, Seungwon [2 ]
Johnson, Jonas T. [2 ]
Bauman, Julie E. [3 ]
Branstetter, Barton F. [4 ]
Heron, Dwight E. [1 ,2 ]
机构
[1] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15232 USA
[2] Univ Pittsburgh, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15232 USA
[3] Univ Pittsburgh, Dept Med, Div Med Oncol, Pittsburgh, PA 15232 USA
[4] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15232 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 95卷 / 03期
关键词
CAROTID BLOWOUT SYNDROME; SQUAMOUS-CELL CARCINOMA; CONCURRENT CHEMOTHERAPY; PLUS CETUXIMAB; PHASE-II; REIRRADIATION; RADIOTHERAPY;
D O I
10.1016/j.ijrobp.2016.02.049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report a 10-year update of our institutional experience with stereotactic body radiation therapy (SBRT) for reirradiation of locally recurrent head and neck cancer, focusing on predictors of toxicity. Methods and Materials: A retrospective review was performed on 291 patients treated with SBRT for recurrent, previously irradiated head and neck cancer between April 2002 and March 2013. Logistic regression analysis was performed to identify predictors of severe acute and late toxicity. Patients with <3 months of follow-up (n=43) or who died within 3 months of treatment (n=21) were excluded from late toxicity analysis. Results: Median time to death or last clinical follow-up was 9.8 months among the entire cohort and 53.1 months among surviving patients. Overall, 33 patients (11.3%) experienced grade >= 3 acute toxicity and 43 (18.9%) experienced grade >= 3 late toxicity. Compared with larynx/hypopharynx, treatment of nodal recurrence was associated with a lower risk of severe acute toxicity (P=.03), with no significant differences in severe acute toxicity among other sites. Patients treated for a recurrence in the larynx/hypopharynx experienced significantly more severe late toxicity compared with those with oropharyngeal, oral cavity, base of skull/paranasal sinus, salivary gland, or nodal site of recurrence (P<.05 for all). Sixteen patients (50%) with laryngeal/hypopharyngeal recurrence experienced severe late toxicity, compared with 6-20% for other sites. Conclusions: Salvage SBRT is a safe and effective option for most patients with previously irradiated head and neck cancer. However, patients treated to the larynx or hypopharynx experience significantly more late toxicity compared with others and should be carefully selected for treatment, with consideration given to patient performance status, pre-existing organ dysfunction, and goals of care. Treatment toxicity in these patients may be mitigated with more conformal plans to allow for increased sparing of adjacent normal tissues. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:973 / 980
页数:8
相关论文
共 19 条
  • [1] Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer
    Biagioli, Matthew C.
    Harvey, Mark
    Roman, Eloy
    Raez, Luis E.
    Wolfson, Aaron H.
    Mutyala, Subhakar
    Han, Hyo S.
    Markoe, Arnold
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04): : 1067 - 1073
  • [2] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [3] Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study
    Comet, Benedicte
    Kramar, Andrew
    Faivre-Pierret, Mathieu
    Dewas, Sylvain
    Coche-Dequeant, Bernard
    Degardin, Marian
    Lefebvre, Jean-Louis
    Lacornerie, Thomas
    Lartigau, Eric F.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (01): : 203 - 209
  • [4] Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
    Forastiere, Arlene A.
    Zhang, Qiang
    Weber, Randal S.
    Maor, Moshe H.
    Goepfert, Helmuth
    Pajak, Thomas F.
    Morrison, William
    Glisson, Bonnie
    Trotti, Andy
    Ridge, John A.
    Thorstad, Wade
    Wagner, Henry
    Ensley, John F.
    Cooper, Jay S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 845 - 852
  • [5] Concurrent Cetuximab With Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck A Single Institution Matched Case-Control Study
    Heron, Dwight E.
    Rwigema, Jean-Claude M.
    Gibson, Michael K.
    Burton, Steven A.
    Quinn, Annette E.
    Ferris, Robert L.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 165 - 172
  • [6] STEREOTACTIC BODY RADIOTHERAPY FOR RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: RESULTS OF A PHASE I DOSE-ESCALATION TRIAL
    Heron, Dwight E.
    Ferris, Robert L.
    Karamouzis, Michalls
    Andrade, Regiane S.
    Deeb, Erin L.
    Burton, Steven
    Gooding, William E.
    Branstetter, Barton F.
    Mountz, James M.
    Johnson, Jonas T.
    Argiris, Athanassios
    Grandis, Jennifer R.
    Lai, Stephen Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1493 - 1500
  • [7] Stereotactic body radiotherapy for head and neck cancer: an addition to the armamentarium against head and neck cancer
    Karam, Irene
    Poon, Ian
    Lee, Justin
    Liu, Stanley
    Higgins, Kevin
    Enepekides, Danny
    Sahgal, Arjun
    Lo, Simon S.
    [J]. FUTURE ONCOLOGY, 2015, 11 (21) : 2937 - 2947
  • [8] Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer
    Lartigau, Eric F.
    Tresch, Emmanuelle
    Thariat, Juliette
    Graff, Pierre
    Coche-Dequeant, Bernard
    Benezery, Karen
    Schiappacasse, Luis
    Degardin, Marian
    Bondiau, Pierre-Yves
    Peiffert, Didier
    Lefebvre, Jean-Louis
    Lacornerie, Thomas
    Kramar, Andrew
    [J]. RADIOTHERAPY AND ONCOLOGY, 2013, 109 (02) : 281 - 285
  • [9] Salvage re-irradiation for recurrent head and neck cancer
    Lee, Nancy
    Chan, Kelvin
    Bekelman, Justin E.
    Zhung, Joanne
    Mechalakos, James
    Narayana, Ashwatha
    Wolden, Suzanne
    Venkatraman, Ennapadam S.
    Pfister, David
    Kraus, Dennis
    Shah, Jatin
    Zelefsky, Michael J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03): : 731 - 740
  • [10] ACR APPROPRIATENESS CRITERIA® RETREATMENT OF RECURRENT HEAD AND NECK CANCER AFTER PRIOR DEFINITIVE RADIATION
    McDonald, Mark W.
    Lawson, Joshua
    Garg, Madhur Kumar
    Quon, Harry
    Ridge, John A.
    Saba, Nabil
    Salama, Joseph K.
    Smith, Richard V.
    Yeung, Anamaria Reyna
    Yom, Sue S.
    Beitler, Jonathan J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1292 - 1298